This was the stock's second consecutive day of losses.
The stock's fall snapped a three-day winning streak.
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
Zacks.com on MSN4d
AbbVie (ABBV) Stock Moves -0.32%: What You Should KnowIn the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day.
Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...
Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback